The most effective strategies for aging well are the most ordinary.
In an age when the desire to remain vital has become a marketplace unto itself, cardiologist Eric Topol offers something rare: a steady hand that separates genuine scientific progress from the theater of longevity commerce. The anti-aging industry has grown vast and largely unregulated, fluent in the language of research yet often untethered from its rigor. Topol's work is a quiet act of public service — reminding us that the most durable paths to healthy aging are neither novel nor expensive, and that wisdom, not optimization, may be the oldest anti-aging tool we have.
- The anti-aging marketplace has exploded into a largely unregulated frontier, selling peptides, sleep protocols, and reimagined vaccines to consumers hungry for solutions that science has not yet fully validated.
- The chasm between what research actually supports and what companies are actively selling is widening — and it is targeting educated consumers who lack the time to scrutinize the evidence themselves.
- Topol methodically examines each category: peptides carry thin evidence and thick marketing, while protein and basic sleep hygiene — unglamorous and nearly free — consistently hold up under scientific scrutiny.
- The industry's core strategy is to dress marketing in the costume of science, using terms like biomarkers and optimization to manufacture an impression of rigor where little exists.
- Topol's prescription is not a product but a posture — slow down, ask who funded the research, ask who profits, and recognize that the most effective interventions for aging well are already within reach.
Eric Topol, a cardiologist with decades of experience studying human aging, has grown frustrated watching the marketplace fill with promises to turn back the clock. Peptides, engineered proteins, elaborate sleep protocols, vaccines reframed as longevity tools — the offerings are endless, the regulations thin, and the gap between genuine science and commercial fiction is growing. Topol has made it his mission to help people navigate that gap.
Peptides illustrate the problem clearly. The theory behind them is appealing — short amino acid chains that signal the body to repair and strengthen — and some show early promise in research. But most products sold to consumers have never been rigorously tested in humans. The marketing is thick, the evidence is thin, and the prices are steep. Protein, by contrast, is one of the few interventions with consistent, solid research behind it: muscle loss accelerates with age, and adequate protein genuinely helps. It is not exotic, not expensive, and perhaps not profitable enough to dominate the conversation.
Sleep hygiene follows a similar logic. The science supporting good sleep as foundational to healthy aging is robust — the body repairs itself, the brain clears waste, the immune system strengthens. Yet the market has surrounded these basics with costly gadgets and supplements, obscuring the fact that a cool dark room and a consistent schedule cost almost nothing. Vaccines, meanwhile, represent legitimate science being actively explored for their role in extending healthspan — but that legitimacy is already being stretched by a longevity industry eager to claim it.
The pattern Topol identifies is consistent: the anti-aging industry has learned to wear science as a costume, using its vocabulary to suggest rigor while often delivering none. It targets people educated enough to recognize the language but too busy to interrogate the evidence. What Topol ultimately offers is not a protocol but a question: before you spend, ask what the evidence actually says, and who profits if you believe the claim. The answers tend to point back toward sleep, movement, protein, connection, and purpose — the unglamorous fundamentals that have always been there, waiting.
Eric Topol, a cardiologist who has spent decades studying how the human body ages, has become increasingly frustrated with what he sees in the marketplace. Walk into any pharmacy, scroll through social media, or open a wellness newsletter, and you'll find an endless parade of products promising to turn back the clock: peptides that claim to rebuild muscle, proteins engineered for longevity, sleep protocols that sound like they belong in a laboratory, vaccines reimagined as anti-aging tools. Some of these interventions have real science behind them. Many do not. And Topol has made it his recent mission to help people tell the difference.
The anti-aging industry is vast and largely unregulated. It preys on a fundamental human desire—the wish to stay young, to remain vital, to dodge the diseases that come with time. That desire is legitimate. The science supporting some interventions is legitimate too. But the gap between what we actually know works and what companies are selling has become a chasm, and it's widening. Topol's work amounts to a careful walk through that landscape, pointing out where the ground is solid and where it's quicksand.
Take peptides, for instance. They're short chains of amino acids, and they've become a fixture in longevity circles. The theory is appealing: peptides can signal your body to do useful things—repair muscle, improve sleep, strengthen bone. Some peptides do show promise in early research. But most of what's being sold to consumers has not been rigorously tested in humans. The evidence is thin, the marketing is thick, and the price tags are substantial. Topol's assessment is straightforward: the hype has outpaced the science by a considerable margin.
Protein is different. Your body needs adequate protein as you age. Muscle loss accelerates in your later decades, and protein is one of the few interventions that consistently shows up in the research as genuinely helpful. This is not exotic. It is not expensive. It is also not sexy enough to sell supplements, which may be why it doesn't get the same cultural attention as the peptides and the biohacking protocols. But the evidence for protein's role in healthy aging is solid, and Topol emphasizes this distinction: some of the most effective strategies are the most ordinary.
Sleep hygiene—the practices that help you sleep better—falls into a similar category. Good sleep is not a luxury; it's foundational to aging well. Your body repairs itself during sleep. Your brain clears metabolic waste. Your immune system strengthens. The science here is robust. But the way sleep is marketed has become almost comical: special mattresses, apps that cost hundreds of dollars, light therapy devices, supplements with names that sound like they were invented by a science fiction writer. Many of these are unnecessary. The basics—a cool, dark room; a consistent schedule; limiting screens before bed—work. They're free or nearly free. They don't generate revenue for anyone, which may explain why they're not what you see advertised.
Vaccines represent another category entirely. Vaccines have prevented or controlled some of humanity's most devastating diseases. New research is exploring whether certain vaccines might help prevent age-related conditions or extend healthspan—the years you live in good health. This is legitimate science being conducted by serious researchers. But it is also being seized upon by the longevity industry as a selling point, sometimes in ways that outrun the evidence. Topol's role here is to clarify what we know, what we're still investigating, and what remains speculative.
The broader pattern Topol identifies is this: the anti-aging marketplace has learned to dress up marketing as science. It uses the language of research—peptides, biomarkers, optimization—to create an impression of rigor where often there is none. It targets people who are educated enough to understand scientific concepts but may not have the time or expertise to evaluate the evidence themselves. And it prices its products at a level that suggests exclusivity and efficacy, when in fact the most effective interventions for aging well are available to everyone and cost nothing.
What Topol is doing, in essence, is asking people to slow down. Before you buy the peptide, before you sign up for the protocol, before you spend thousands on the device or the supplement, ask yourself: What does the evidence actually say? Who funded the research? Who profits if I believe this claim? The answers to those questions often reveal that the most reliable path to aging well is not the most glamorous one. It involves sleep, movement, protein, social connection, and purpose. It involves the things your grandmother probably told you to do. It is not a secret. It cannot be optimized into something better than it already is. And that, perhaps, is why it's so easy to overlook.
Notable Quotes
The anti-aging marketplace has learned to dress up marketing as science, using clinical language to create an impression of rigor where often there is none.— Eric Topol's assessment of industry practices
The Hearth Conversation Another angle on the story
Why does the anti-aging industry have such a grip on people's imagination right now?
Because aging itself is frightening, and the industry has learned to speak the language of science while selling hope. When you're worried about decline, a peptide with a clinical-sounding name feels more reassuring than "get good sleep."
But some of these interventions do have research behind them, right?
Yes, some do. The problem is distinguishing between early-stage research that shows promise and finished science that actually works in humans. The industry doesn't make that distinction. It treats a promising mouse study the same way it treats a large human trial.
What about the people who can afford these things? If someone has the money and wants to try peptides, what's the harm?
The harm is partly financial—you're paying for something unproven when proven interventions are free. But it's also epistemic. You're training yourself to believe that aging is a problem that money solves, rather than a condition that requires attention and discipline.
You mentioned protein as genuinely helpful. Why isn't that the story everyone's telling?
Because protein is boring. It doesn't require a subscription. It doesn't make anyone rich. The companies that profit from longevity have no incentive to tell you that eating chicken and beans might be enough.
So what should someone actually do if they want to age well?
The unsexy answer: sleep consistently, move your body, eat enough protein, maintain relationships, have something that matters to you. None of it is new. None of it is proprietary. And the evidence for all of it is strong.